The increasing expansion of the biologics market, rising demand in the atopic dermatitis treatment market, and growing adoption of the asthma biologics market are significantly contributing to the growth of advanced targeted therapies worldwide. Dupixent (dupilumab), a monoclonal antibody designed to target key pathways involved in type 2 inflammation, has emerged as an...